Vigabatrin Inhibits Seizures and mTOR Pathway Activation in a Mouse Model of Tuberous Sclerosis Complex
Figure 1
VGB treatment inhibited seizures and moderately improved survival in Tsc1GFAPCKO mice.
(A) Representative EEG recordings of Tsc1GFAPCKO mice treated with vehicle or vigabatrin. (B) Seizures started to develop in vehicle-treated Tsc1GFAPCKO mice (Fig. 1A, KO + Veh) around 3 weeks and became progressively more frequent with age. VGB treatment (KO + VGB) almost completely suppressed the development of seizures in Tsc1GFAPCKO mice (*p<0.05 by one-way ANOVA, n = 13 mice/group). (C) Survival analysis showed that vehicle-treated Tsc1GFAPCKO mice die prematurely with 50% mortality around 7 weeks of age and 100% mortality by 11 weeks. VGB treatment modestly improved the survival of Tsc1GFAPCKO mice compared to the vehicle treated Tsc1GFAPCKO mice (*p<0.05 by Chi-Square test, comparing the two groups, n = 13 mice/group), but all VGB-treated mice still died by age of 14 weeks. KO = Tsc1GFAPCKO mice, Veh = vehicle, VGB = vigabatrin.